GOTHENBURG, Sweden, Jan. 23, 2024 /PRNewswire/ — Stena Sessan AB (‘Stena Sessan’), which holds more than 90 per cent of the shares and votes in Concordia Maritime AB (publ) (‘Concordia Maritime’), has requested that a compulsory buy-out of the remaining shares in Concordia Maritime be initiated.

Against the above background, the Board of Directors of Concordia Maritime has decided to apply for delisting of Concordia Maritime’s class B shares from Nasdaq Stockholm. The last day of trading in the class B share will be announced after Concordia Maritime has submitted the application and received a decision from Nasdaq Stockholm.

The Board of Directors of Concordia Maritime has furthermore, at the request of Stena Sessan, decided to convene an Extraordinary General Meeting to be held on 22 February 2024 for resolutions on, inter alia, election of new members of the Board of Directors. The notice will be published through a separate press release.

This information is information that Concordia Maritime AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the below contact persons, on 23 January 2024 at 14:00 CET.

CONTACT:

For more information, please contact:Stefan BrockerChairman of the Board of Directors, Concordia Maritime AB+46 709 777 687stefan.brocker@msa.se

Erik LewenhauptCEO, Concordia Maritime AB+46 704 855 188erik.lewenhaupt@concordiamaritime.com

The following files are available for download:

https://mb.cision.com/Main/1948/3913973/2556765.pdf

Concordia Maritime – Press release – Delisting – 20240123 (PDF)

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

Glodon AEC Connect Day 2025 Returns, Featuring Executives from Leading Indonesian State-Owned and Private Construction Companies

JAKARTA, Indonesia, May 13, 2025 /PRNewswire/ — Glodon is once again organizing AEC…

AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis

SHANGHAI, Feb. 19, 2024 /PRNewswire/ — AffaMed Therapeutics ("AffaMed"), a biotechnology company…

Mega Matrix Inc. Announces 2024 Year-End Financial Results

SINGAPORE, March 27, 2025 /PRNewswire/ — Mega Matrix Inc. ("MPU" or the…